As we come upon the 10th anniversary of the Medicare Part D program, is it still living up to its promise? What can be done to improve it?

Contributors Respond

Conversations on Innovations in the Biopharmaceutical Pipeline

09.23.13 | By

With more than 5,000 medicines in development globally, the prospects for incredible breakthroughs in medicine – many of which may one day help those suffering from diseases that are currently untreatable – are exceedingly bright.

Having Conversations on the Biopharmaceutical Pipeline

09.18.13 | By

There are more than 5,000 new medications in the research and development pipeline. Some of these medications may one day result in effective treatments for diseases and conditions that exact a tremendous personal and financial toll on patients around the country and the world.

Conversations Wrap Up

09.17.13 | By

Biopharmaceutical scientists work daily to identify and develop potential preventative and therapeutic medicines for some of the most difficult conditions and diseases, with the unified goal of helping people live longer and healthier lives. Rarely have we been more successful at achieving this goal than with the development and global utilization of vaccines  

Conversations Contributors - Paul Howard

Paul Howard, Ph.D., is a Manhattan Institute senior fellow and director of the Manhattan Institute's Center for Medical Progress. He is the managing editor of Medical Progress Today, a blog providing a forum for economists, scientists, and policy experts to explore the scientific, regulatory, and market frameworks that will best support twenty-first century medical innovation.

The Public Health Value of Vaccines Acceptance

09.15.13 | By

So far this year, according to the Centers for Disease Control and Prevention (CDC), 159 cases of measles have been reported in 16 states  – 36 percent of those occurring in children less than five years of age.

Strides in Vaccine Development

09.13.13 | By

Despite some tremendous strides in vaccine development over the years, vaccines remain a major public health challenge for patients and their families throughout the world. This week we released our Medicines in Development: Vaccines report, which shows there are more than 270 vaccines in the pipeline to prevent and/or treat a wide array of diseases, including various forms of cancer and neurological disorders. 

Conversations Contributors - Robyn Swirling

Robyn Swirling is the Online Organizing & Outreach Coordinator at Advocates for Youth. She primarily works on the 1 in 3 campaign, encouraging people to tell the stories of their experience with abortion, managing the campaign's digital media presence, and working with bloggers and other influencers to further the campaign's reach.

Conversations Contributors - Roberta DeBiasi

Roberta Lynn DeBiasi, MD, recently joined Children’s National Medical Center and the George Washington University School of Medicine and Health Sciences as an associate professor of Pediatrics in the Division of Pediatric Infectious Diseases, and an investigator at Children’s Research Institute in the Center for Cancer and Immunology.

Conversations Contributors - Christophe Weber

Christophe was appointed President, Vaccines in April 2012. He is a member of the Corporate Executive Team.

He was named President Designate of Vaccines in January 2011. Prior to this, he was Senior Vice President and Regional Director, Asia Pacific, responsible for GSK operations in Asia Pacific from 2008.


Subscribe to RSS - conversations